Study: MDs refer profitable patients to their ASCs
This isn't too surprising, but it's not something policymakers will like, either. A new study of referral patterns in the Philadelphia and Pittsburgh metros suggests that physicians who are high-admitters to physician-owned ASCs send far more privately insured patients to those facilities, while sending Medicaid enrollees to hospital outpatient departments, in many cases. The study, published in Health Affairs and completed through the University of Chicago, looks at whether having a stake in an ASC affects the types of patients a physician would refer to a facility. Research found that for the top 50 percent of physician referrals to ASCs, 45 percent of Medicaid patients were sent to hospital outpatient departments, while 92 percent of privately insured patients were sent to physician-owned ASCs.
Folks, these numbers seem to pretty much clinch the argument that ASCs keep the best-paying patients for themselves, while blocking the poor from getting whatever benefits the specialized ASC services might offer. Looks like this could kick off some heated discussions on Capitol Hill.
To get more information on the study:
- read the Health Affairs report
- read this Modern Healthcare article (reg. req.)
Related Articles:
NY accuses ASCs of collecting overpayments. Reports
Number of PA ASCs keeps growing, but profits level off. Report
CMS updating rules for ASC Medicare participation. Report
Doctors sue HealthSouth over surgery centers sale. Report
Profits way up for Penn ASCs. Report
Georgia physicians battle for looser ASC regs. Report
Ohio bill would force hospitals to have 24x7 EDs. Report
Comments
Medicaid DOES NOT recognize cost of doing business and does not reimburse facility fees. In fact if Medicare decides to go ahead with the 10% cuts in June, I would bet that NO Medicare patient will be done in an ASC either. This is simple economics. I hope they did not spend a few million dollars of funding for this study.
Post new comment
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies




